The new agency will operate under the name Deerfield Group, and will also include Verge Scientific Communications.
Deerfield Agency announced that it has agreed to acquire healthcare marketing and advertising firm Embedded.1 After the acquisition is completed, Deerfield Agency, Embedded, and Verge Scientific Communications will operate under the new brand Deerfield Group.
In a press release, Deerfield Agency announced the Frank Burrell will serve as CEO of the newly formed Deerfield Group. In the same press release, he said, “With shifting market dynamics and industry trends, our clients are in even greater need of smart, integrated marketing and communications strategies and agile partners who can help maximize their efforts and resources to ensure the greatest possible impact for their business. Over the last 10 years, Deerfield Group has continued to evolve to shape new services, solutions, and ways of working that enable us to truly deliver for our clients. We are thrilled to welcome Embedded, whose seasoned team adds to our bench of marketing and communications strategists—enhancing and expanding how we plan and execute for clients every day. We have also completed a leadership alignment to drive greater collaboration and integration across our work for clients and the organization."
Dominic Viola is a founding partner of Embedded and will become president of integrated marketing of Deerfield Group. In the same press release, he said, “As the life sciences space evolves, we understand the clear need to deliver insight-driven strategy and integrated marketing campaigns for clients. The partnership with Deerfield expands our capacity for impact with clients as we create the destination for these companies across the marketing and communications continuum.”
Deerfield also announced the following roles for the newly formed Deerfield Agency: Joshua Benson as COO, Paul Brown as partner and board member, Lissette Steele as chief insights officer, and Amanda Sellers as president of global communications.
In March, Deerfield Agency announced that Bill Veltre had joined the company as executive vice president and head of media.2
In a press release issued at the time, Burrell said, “Bill's appointment signifies an exciting milestone for Deerfield Agency as our media service offerings grow and we continue to enhance our media insights and reporting capabilities. Recognized as a dedicated media-enthusiast and provocative thought leader, Bill will explore new opportunities in digital marketing and reporting, helping our clients drive meaningful engagement with patients and health care professionals."
In the same press release, Veltre said, “I am thrilled to join the Deerfield team and play a key role in driving the agency's continued success. Critical to pharmaceutical marketing today is how to effectively engage with HCPs and patients and how we leverage insights to improve the effectiveness of marketing efforts. Deerfield has built a true marketing engine powered by omnichannel approaches, data and analytics, and creative strategy. I'm looking forward to partnering with my new colleagues to continue to refine our approaches and help our clients deliver on the promise of their products."
In February, the company also announced that Eric Steckelman joined as executive vice president of business development.3 In a press release, Burrell said, “"Eric's appointment marks an exciting chapter for Deerfield Agency as we continue to expand our capabilities and drive innovation as an Agency of Brand® in the healthcare and life sciences industries. With a proven track record in new business growth and development, along with expertise in assessing market trends and opportunities, we are confident that Eric will play a key role in deepening and expanding client relationships and broadening visibility for the agency."
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.